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Abstract
Background: Neuromyelitis optica (NMO) is a severely disabling autoimmune disorder of the central nervous system, which
predominantly affects the optic nerves and spinal cord. In a majority of cases, NMO is associated with antibodies to
aquaporin-4 (AQP4) (termed NMO-IgG).
Aims: In this study, we evaluated a new multiparametric indirect immunofluorescence (IIF) assay for NMO serology.
Methods: Sera from 20 patients with NMO, 41 patients with multiple sclerosis (MS), 30 healthy subjects, and a commercial
anti-AQP4 IgG antibody were tested in a commercial composite immunofluorescence assay (‘‘Neurology Mosaic 17’’;
Euroimmun, Germany), consisting of five different diagnostic substrates (HEK cells transfected with AQP4, non-transfected
HEK cells, primate cerebellum, cerebrum, and optic nerve tissue sections).
Results: We identified AQP4 specific and non-specific fluorescence staining patterns and established positivity criteria.
Based on these criteria, this kit yielded a high sensitivity (95%) and specificity (100%) for NMO and had a significant positive
and negative likelihood ratio (LR+=‘,L R 2=0.05). Moreover, a 100% inter- and intra-laboratory reproducibility was found.
Conclusions: The biochip mosaic assay tested in this study is a powerful tool for NMO serology, fast to perform, highly
sensitive and specific for NMO, reproducible, and suitable for inter-laboratory standardization as required for multi-centre
clinical trials.
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Introduction
Neuromyelitis optica (NMO) is a severely disabling autoimmune
disorder of the central nervous system, which mainly affects the
optic nerves and spinal cord [1,2]. In the majority of cases, NMO
is associated with autoantibodies to the water channel aquaporin-4
(AQP4) (termed NMO-IgG) [3,4]. Anti-AQP4 antibodies have
also been found in patients with isolated longitudinally extensive
transverse myelitis and in patients with isolated optic neuritis,
conditions which are considered limited or inaugural forms of
NMO [5–7]. In addition, anti-AQP4 antibodies have been found
in a subset of patients with connective tissue disorders (CTD) such
as lupus erythematosus (SLE), Sjogren’s syndrome and co-existing
NMO spectrum disorders (NMOSD) [8–10].
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the detection of NMO-IgG have been developed [11]. However,
most of these assays are available only at few specialized
laboratories. Moreover, most of them lack independent standard-
ization and validation, and no generally accepted gold standard
assay exists.
The present study aimed to evaluate a new commercially
available multiparametric indirect immunofluorescence (IIF) assay
in distinguishing NMO from MS patients. This assay consists of an
array of five different diagnostic substrates including HEK cells
transfected with AQP4, non-transfected HEK cells, and three
monkey tissue sections (cerebellum, cerebrum, and optic nerve).
The assay was evaluated through the following steps: 1.
Characterization of distinct immunofluorescence staining patterns.
2. Correlation between staining patterns and the patients’ clinical
diagnoses. 3. Evaluation of the diagnostic sensitivity, specificity,
and clinical utility (as assessed by calculation of likelihood ratios) of
each pattern. 4. Analysis of the assay’s inter- and intra-laboratory
reproducibility.
Our results show that this IIF assay has high sensitivity and
specificity and represents a powerful tool for NMO serology,
permitting the identification of different AQP4 specific and non-
specific patterns. Moreover this assay is fast to perform, highly
reproducible and suitable for inter-laboratory standardization.
Materials and Methods
Ethics Statement
This study was approved by the Ethical Committee of the San
Luigi University Hospital (approval n. 1704). An informed written
consent was obtained from each individual.
Patients and Healthy Controls
Patients and controls were recruited from five MS centres at the
following university hospitals: S. Luigi Gonzaga (Orbassano, Italy),
Policlinico Gemelli (Rome, Italy), Binaghi (Cagliari, Italy),
Modena (Italy), and Charles (Prague, Czech Republic).
Demographic and clinical characteristics of patients and
controls are shown in Table 1. All samples were processed in a
blinded fashion.
Identification of NMO patients. NMO patients were
selected from a total of 236 serum samples which our laboratory
had received for diagnostic purpose in 2009 and 2010. Clinical
data were provided by the senders using a semi-structured
questionnaire containing the 2006 Wingerchuk criteria (i.e. the
minor criterion of NMO-IgG seropositivity was not considered to
avoid selection bias towards NMO-IgG positive cases) [2]. Based
on the data reported in the questionnaires, 20/236 cases met the
clinical and radiological criteria for NMO. These cases were
classified as ‘‘clinically and radiologically defined NMO’’ (N=20)
and included in the present study (Figure 1). Sixteen of these 20
patients were treatment-free at the time of blood withdrawal (12
treatment-naı ¨ve, 1 previously treated with immunosuppressive
drugs, and 3 previously treated with immunosuppressive and
immunomodulant drugs); the remaining 4 NMO patients were
under immunosuppressive (26azathioprine) or immunomodulato-
ry therapy (16interferon-beta, 16glatiramer acetate) at the time of
blood withdrawal. Conversely, samples from patients who did not
meet these criteria or from patients from whom no sufficient data
was available to evaluate whether the criteria were met were
excluded (N=216).
Selection of MS patients and healthy controls. As
controls, 41 patients with definite relapsing remitting multiple
sclerosis (RRMS) according to the revised McDonald’s criteria
[12], naı ¨ve to any immunomodulatory therapy, and 30 healthy
volunteers were enrolled. These samples were not selected from
the 236 sera described above, but they were specially selected for
the present study.
BioChip Mosaic
TM Indirect Immunofluorescence Assay
(IIF)
Samples were tested for NMO-IgG using a multiparametric
commercial IIF assay (‘‘Neurology Mosaic 17’’, Euroimmun,
Luebeck, Germany); the 5 kits used for the present study were
purchased by S. Luigi Gonzaga University Hospital. This assay is
provided as a ready-to-use kit consisting of microscopy slides with
five reactions fields, each containing an array of five different
biological substrates (i.e. HEK cells transfected with AQP4-Ab,
non transfected HEK cells, and primate cerebellum, cerebrum and
optic nerve cryosections), positive and negative control samples,
and a pre-diluted goat anti-human IgG secondary antibody
conjugated to fluorescein isothiocyanate (FITC). The substrates
are applied to coated cover glasses by the manufacturer, which are
then automatically cut to millimetre-sized fragments (termed
biochips) and transferred to the reaction fields. This approach
allows simultaneous testing of patient samples on several
substrates. Briefly, 25 ml of a 1:60 diluted serum samples were
applied to each reaction field according to the manufacturer’s
protocol. After 30 min of incubation at room temperature, the
slides were washed with PBS-Tween (0,002%) for 5 minutes. Then
20 ml of fluorescein-labelled anti-human IgG were applied to each
reaction field and incubated with the BioChip slides for
30 minutes. After an additional 5 min wash with PBS-Tween
(0,002%), a glass coverslip was applied to each slide. The
mounting medium contained an antifading agent and 4,6-
diamidino-2-phenylindole (DAPI) for nuclear staining (ProLong
Gold with DAPI, Invitrogen Ltd., Renfrew, UK). Sections were
analysed under a DMIRE2 Leica fluorescence microscope (Leica,
Milan, Italy) with a 406 oil immersion lens. Pictures were
acquired with a digital camera model DC250 Leica, using the
acquisition software Qfluor550 Leica.
Positive and negative human control sera provided by the
manufacturer were tested in each working session; in addition, a
goat polyclonal anti-AQP4 IgG (H19, sc-9887, Santa Cruz
Biotechnology Inc., Santa Cruz, CA) was tested as a supplemental
positive control in a 1: 500 dilution. All samples and controls were
tested in a blinded fashion by two different operators (LG and
FM).
Evaluation of the Assay
Characterization of fluorescence staining patterns.
Based on anatomic and morphological characteristics, a number
of typical staining patterns were obtained by incubating the
various substrates with i.) a commercial goat anti-human AQP4
IgG antibody, ii.) anti-AQP4 IgG antibody positive control sera
(included in the IIF kit), iii.) 91 serum samples from patients with
NMO and controls.
Comparison between fluorescence patterns and patients’
clinical diagnosis. The different fluorescence staining patterns
were associated to the clinical status of the subjects (NMO, MS, or
healthy).
Reproducibility analysis. To evaluate the assay’s intra-
laboratory reproducibility, positive and negative control samples
included in the kit were tested in 20 independent runs. Moreover,
each serum sample was tested in our laboratory twice by two
different operators in a blinded fashion (LG and FM). Further-
more, the inter-laboratory reproducibility was evaluated by
blinded testing of 9 serum samples in our laboratory and at the
Assay for Neuromyelitis Optica Serology
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Germany.
Statistical analyses. Sensitivity and specificity for each
pattern were calculated using the clinical and MRI diagnosis of
NMO as reference standard. Clinical utility of each substrate was
then evaluated by comparing likelihood ratios (LR) [13] for
positive (sensitivity divided by 1- specificity) and negative (1-
sensitivity divided by specificity) test results. LRs of .10 for a
positive test result or ,0.1 for a negative test result are expected to
yield a conclusive change in the post-test odds of disease presence.
The inter-rater agreement kappa test was used to evaluate the
agreement between paired combinations of results and centers for
the case of positive and negative classification (ordinal outcomes):
K coefficient is an index of agreement, ranging from 0 (no
agreement beyond chance) to/1 (perfect agreement), calculated as
a measure of agreement corrected for chance [14,15]. All statistical
analyses were realized using the GraphPad PrismH Program
Version 4.0 (GraphPad Software Inc., San Diego, CA, USA).
Results
Characterization of staining patterns
Definition of anti-AQP4 specific and non-specific
fluorescence staining. The anti-AQP4 positive human serum
Table 1. Demographic and clinical characteristics of subjects.
NMO (n=20) MS (n=41) HC (n=30)
Demography
Male/Female 2 (10%)/18 (90%) 16 (39%)/25 (61%) 14 (47%)/16 (53%)
Median age at blood withdrawal, years 45 (19–72) 32 (10–69) 32 (22–58)
Median age at onset, years 31(13–62)
* 28 (5–54)
*
Clinical features
Optic neuritis 20/20 (100%) 20/41 (49%)
Monophasic 5/20 (25%) 16/20 (80%)
Recurrent 15/20 (75%) 4/20 (20%)
Transverse Myelitis 20/20 (100%) 19/41 (46%)
Monophasic 5/20 (25%) 14/19 (74%)
Recurrent 15/20 (75%) 5/19 (26%)
Imaging and CSF
Initial MRI brain, does not meet MS criteria
** 20/20 (100%) 6/41 (15%)
MRI spinal cord lesion $3 segments 20/20 (100%) 0/41 (0%)
CSF positive for OB
*** 4/18 (22%) 34/37 (92%)
NMO: neuromyelitis optica, MS: multiple sclerosis, HC: healthy controls, MRI: magnetic resonance imaging, CSF: cerebrospinal fluid, OB: oligoclonal bands.
*One NMO patient and one MS patient are pediatric.
**According to Wingerchuk 2006, where MRI Paty criteria for MS were included.
***CSF data were not available for 2 NMO patients and for 4 MS patients.
doi:10.1371/journal.pone.0038896.t001
Figure 1. Recruitment of NMO patients, MS patients and HC. OD: Other diseases, NMO: neuromyelitis optica, MS: multiple sclerosis, HC:
healthy controls.
doi:10.1371/journal.pone.0038896.g001
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IgG antibody were used as positive controls to define the anti-
AQP4 specific staining for each substrate (Figure 2: 1A, 1B, 1C,
1D, 1E). In the cell membrane of the AQP4 transfected HEK cells
the antibodies formed a flat, smooth, or fine granular fluorescence,
whereas no staining was found with the non-transfected HEK cells
(Figure 2: 1A, 1B). Characteristic NMO-IgG staining of the pia
mater (when present in the tissue section) and microvasculature in
the gray and white substance was observed (Figure 2: 1C, 1D, 1E).
In addition, the extracellular spaces in the granular layer of
primate cerebellum were strongly stained resulting in a mesh wire-
like pattern (Figure 2: 1C). Finally, the white matter of primate
cerebrum, cerebellum, and optic nerve showed staining of a very
dense and irregular network of fine filamentous structures, which
was defined as ‘‘typical AQP4 white matter staining’’ (Figure 2:
1C, 1D, 1E; Figure 3A).
Figure 2. Fluorescence staining patterns as observed with positive and negative controls provided by the manufacturer (column 1
and 2, respectively), an anti-AQP4 antibody positive human serum sample (column 3), and an anti-AQP4 antibody negative human
control sample (column 4). The biochip mosaic consists of 5 substrates: HEK cells transfected with full length recombinant human AQP4 (row A),
non-transfected HEK cells (row B) and cryosections of primate cerebellum (row C), cerebrum (row D) and optic nerve (row E). Bound IgG was
visualized using secondary antibodies labeled with FITC (green). Cell nuclei, stained with DAPI, are shown in blue. Magnification 406. GL: granular
layer; WM: white matter; DAPI: 4,6-diamidino-2-phenylindole; FITC: fluorescein isothiocyanate.
doi:10.1371/journal.pone.0038896.g002
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from MS patients and HC, which was characterized by a regular
network of filamentous structures, predominantly orientated in
parallel with the axons (Figure 3B).
Definition of four distinct staining patterns. By testing 91
serum samples, four distinct staining patterns were identified.
Their complete spectrum is represented in Figure 4.
– Pattern A was characterized by the presence of staining of the
cell membrane of the AQP4-transfected HEK cells in the
absence of staining of the membrane of the non-transfected
HEK cells, mesh wire like staining in the granular layer, pia
mater (when present) staining and the ‘‘typical AQP4 white
matter staining’’ as described above in all primate tissue
sections. (Figure 2: 3A, 3B, 3C, 3D, 3E).
– Pattern B was characterized by the presence of the ‘‘typical
AQP4 white matter staining’’ as described above in one or
more primate tissue sections in the absence of any other
staining (Figure 2: 4A, 4B, 3C, 3D, 3E).
– Pattern C was characterized by the presence of the ‘‘atypical
white matter staining’’ as described above detectable on one or
more primate tissues in the absence of any other staining
(Figure 3B, Figure 2: 4A, 4B).
– Pattern D was defined by the complete absence of staining in all
five substrates (Figure 2: 2A, 2B, 2C, 2D, 2E; 4A, 4B, 4C, 4D,
4E).
Figure 3. ‘‘Typical’’ (A) and ‘‘atypical’’ (B) white matter
fluorescence staining as observed with anti-AQP4 positive
NMO (A) and anti-AQP4 negative MS (B) human serum
samples, respectively. Bound IgG was visualized using secondary
antibodies labeled with FITC (green). Cell nuclei, stained with DAPI, are
shown in blue. Magnification 406. NMO: neuromyelitis optica; MS:
multiple sclerosis; DAPI: 4,6-diamidino-2-phenylindole; FITC: Fluorescein
isothiocyanate.
doi:10.1371/journal.pone.0038896.g003
Figure 4. Differential distribution of IIF staining patterns in five diagnostic substrates following incubation with serum samples
from patients with NMO or controls. The corresponding staining patterns (A, B, C, D; typical and atypical white matter staining), as defined in the
results section, are indicated, together with the final evaluation of positivity or negativity for anti-AQP4 antibodies, and the healthy volunteers’ clinical
status. NMO: neuromyelitis optica, MS: multiple sclerosis, HC: healthy controls, CNT 1: commercial goat polyclonal anti-human AQP4 IgG (H19, Santa
Cruz Biotechnology), CNT 2: human anti-AQP4 positive serum provided by the manufacturer, CNT 3: human anti-AQP4 negative serum provided by
the manufacturer, TC=transfected cells, NTC=non-transfected cells, ON=optic nerve.
doi:10.1371/journal.pone.0038896.g004
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clinical diagnosis
We associated the four different patterns with the clinical status
(NMO, MS, or healthy) of each subject. Pattern A was found in
19/20 (95%) serum samples from patients diagnosed with NMO
according to clinical and MRI findings, and it was not observed
with any MS sample nor with any healthy control sample (HC).
Pattern B and C were present in a subset of control patients.
Pattern D was associated with NMO in only one single case but
was frequently observed with the MS and HC controls. See
Table 2 for details.
Sensitivity, specificity and likelihood ratios (LR)
The clinical and MRI diagnostic criteria for NMO [2] were
considered as the ‘‘gold standard’’ for sensitivity, specificity, and
LR analyses for each pattern. Pattern A showed 95% sensitivity
and 100% specificity for NMO. Accordingly, pattern A had a very
high positive LR (LR+, ‘; should be .10 to be clinically useful)
and a very low negative likelihood ratio (LR2, 0.05; should be
,1). To note, pattern A did not include the microvasculature
staining, which has been so far considered a typical NMO-IgG
feature: in fact, it was observed in 9/20 (45%) NMO patients (the
patient negative for pattern A was also negative for microvascu-
lature staining), and in 4/71 control sera (1 MS and 3 HC), thus
showing 45% sensitivity and 95% specificity for NMO. Patterns B
and C showed no sensitivity for NMO, while Pattern D showed
5% sensitivity.
Sensitivity, specificity, and LR for NMO were calculated also by
considering the ‘‘typical AQP4 white matter staining’’ in each
single substrate of biochip mosaic. All substrates showed 95%
sensitivity for NMO and a LR2 of 0.05, but the AQP4-transfected
HEK cells had a higher specificity (100%) and LR+ (‘) than the
other substrates (specificity, 94–96%; LR+, 15.83–23.75). Results
are summarized in Table 3.
Reproducibility
Intra-laboratory reproducibility. To evaluate the assay’s
intra-laboratory inter-run and inter-rater reproducibility, positive
and negative control samples (provided by the manufacturer) were
tested by two blinded operators (LG, FM) in 20 independent runs.
In addition, all 91 serum samples were tested and evaluated in a
blinded fashion in our laboratory by the two operators (LG, FM) in
different working sessions. A 100% inter-rater (K=1) and a 100%
inter-run agreement (K=1) was found.
Inter-laboratory reproducibility. Nine serum samples (4
from NMO patients and 5 from HC) provided by the Multiple
Sclerosis Centre at the Charles University Hospital (Prague, Czech
Republic) were tested in parallel in our laboratory (CReSM,
Orbassano, Turin) and at the Institute of Experimental Immu-
nology, affiliated to Euroimmun, in Luebeck, Germany, to
evaluate the assay’s inter-laboratory variability. Raters at both
laboratories were blinded to the donors’ clinical status. A 100%
concordance between laboratories was found (K=1).
Discussion
NMO serology has become an important aspect in the
diagnostic workup of patients with NMO and has been included
in the revised diagnostic criteria for this condition [2]. More
recently, anti-AQP4 antibodies have been found also in a subset of
patients with isolated transverse myelitis [5], patients with isolated
optic neuritis [16,6,7], and patients with NMOSD and co-existing
CTD [8–10], leading to an increase in the number of clinical
conditions that require testing for anti-AQP4 antibodies.
Testing for anti-AQP4 antibodies is important not only also
from a diagnostic but also from a therapeutic point of view, since
treatment options differ considerably between NMO and MS.
Immunomodulatory drugs (i.e. interferon beta, natalizumab and
fingolimod) are believed to be preferential in MS, while their use
could be detrimental in NMO. In particular, interferon beta was
shown to trigger severe disease exacerbation in patients with
NMOSD [17,18]. Similarly, a failure of natalizumab to control
disease activity in anti-AQP4 antibody positive NMOSD patients
was reported [19,20]. Very recently, extensive brain lesions were
reported in an anti-AQP4 antibody positive patient following
treatment with fingolimod (FTY720) [21]. In contrast, immuno-
suppressive drugs such as azathioprine, rituximab, or mycophe-
nolate, which are not among the first line treatments for MS, have
been shown to be effective in NMO [22–26].
Over the last couple of years, several assays have been
developed for the detection of anti-AQP4 antibodies [11]
including indirect immunohistochemistry (IHC) on mouse or
monkey brain sections [3,27,28], cell based assays (CBA) [28–30],
a radioimmunoprecipitation assay [31], fluoroimmunoprecipita-
tion assays [30,32], an enzyme linked immunosorbent assay [33],
FACS based assays [34,35], and western blot analysis [36].
However, the sensitivity and specificity of these assays differed
markedly (sensitivity ranges from 33% to 91%, specificity from
85% to 100%) [11]. Moreover, some methods have yielded
discordant results when applied at different laboratories, and
incongruous results were found with identical samples tested in
different assays in some studies [32–34], suggesting a possible lack
of standardization and validation of the various in-house assays
currently available. Accordingly, none of these methods has been
so far generally accepted as a ‘‘gold standard’’ or reference
method.
However, highly standardized and reproducible assays for the
detection of anti-AQP4 antibodies are crucial for large multi-
centre studies aiming to better define the epidemiological, clinical,
and pathological features of patients with NMO and their response
to treatment with respect to the patients anti-AQP4 antibody
serostatus, as previously pointed out by Fazio and colleagues [37].
Moreover, only if standardized assays are applied, results are
comparable between studies.
The aim of the present study was to perform a systematic
evaluation of a new multiparametric indirect immunofluorescence
assay (‘‘Neurology Mosaic 17’’, Euroimmun, Luebek, Germany).
This assay potentially meets some of the requirements for future
multicentre trials. First, as a commercial assay it is not restricted to
a few specialized laboratories as many of the in house-assays used
in previous studies and thus available for independent evaluation.
Table 2. Association between fluorescence patterns and
clinical status of all the analyzed samples (2 commercial anti-
AQP4 positive controls, 20 NMO samples, 41 MS samples, 30
healthy subjects).
POSITIVE
CONTROLS NMO MS HC
PATTERN A 100% (2/2) 95% (19/20) 0% (0/41) 0% (0/30)
PATTERN B 0% (0/2) 0% (0/20) 5% (2/41) 7% (2/30)
PATTERN C 0% (0/2) 0% (0/20) 7% (3/41) 3% (1/30)
PATTERN D 0% (0/2) 5% (1/20) 88% (36/41) 90% (27/30)
NMO: neuromyelitis optica, MS: multiple sclerosis, HC: healthy controls.
doi:10.1371/journal.pone.0038896.t002
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potentially reducing the variability frequently associated with in-
house assays. Third, cells and tissues are produced by the
manufacturer at large scale and stored in liquid nitrogen until
array assembly; this potentially allows eliminating assay variability
due to changes over time in transfection rates or in tissue quality.
Fourth, the assay is relatively simple to perform and less time-
consuming and labour-intensive if compared to immunoprecipi-
tation or FACS analysis, which require rather sophisticated
techniques such as cell culture and cell transfection to be available
at the performing laboratory. Moreover, the assay can potentially
be used to obtain semi-quantitative results on anti-AQP4
antibodies titres. Monitoring AQP4-Ab titre dynamics over time
could be important, since recent evidence indicates that anti-
AQP4 titers might correlate with disease activity in NMO
[11,29,38], though we could not test the latter point due to a
lack of suitable follow-up samples. Finally, the use of biochips
allows assessing several substrates (transfected cells, brain tissue
sections) in a single session, eliminating the need for multiple
incubations and reducing the total serum volume required to 2 ml.
These features render the assay a possible candidate for future
trials in NMO.
To evaluate the assay’s diagnostic performance, we tested a
series of 91 serum samples (20 NMO patients, 41 MS patients and
30 HC), positive and negative controls provided by the manufac-
turer, and a commercial antibody to human AQP4 to define
AQP4-Ab specific and non-specific staining patterns on the
various substrates included in the biochip. This led us to the
identification of 4 different fluorescence patterns (termed A, B, C,
D). Of particular note, we identified two distinct patterns of white
matter staining, which may be helpful in the interpretation of
fluorescence patterns on primate brain sections as they help
avoiding false positive results. By correlating the various fluores-
cence patterns observed with the clinical status of the analysed
subjects, we established pattern A as the only staining pattern that
is highly specific for AQP4. This pattern was found with both
positive controls and with 19/20 sera from patients with NMO,
corresponding to a sensitivity of 95% for NMO. Sensitivity,
specificity and LRs were evaluated also for each substrate
separately, i.e. for the transfected cells and the three brain tissue
sections. All substrates showed the same sensitivity (95%) for
NMO, but different specificity values. While the transfected cells
had a 100% specificity, the three monkey tissues showed lower
specificity rates due to the presence of AQP4-like white matter
positive staining in some MS patients and HC (Table 3). Given the
fact that all established characteristics of AQP4 antibody-specific
staining were missing and the CBA was negative, the presence of
white matter staining in these rare MS and HC patients is likely to
indicate the presence of serum antibodies directed against so far
unknown antigens other than AQP4.
Sensitivity, specificity and LR values obtained by using either
the whole biochip mosaic or the transfected cells substrate alone
were the same. Formally, the cell-based assay would thus be
sufficient for the detection of antibodies against AQP4. However,
this multiparametric assay allows to test the same sample
simultaneously on different substrates and by two different
methods (i.e. IHC and CBA), increasing the strength of the result.
Moreover, a portion of patients with NMO or NMO spectrum
diseases are negative for anti-AQP4 antibodies [3,27,39]. In these
patients, other autoimmune conditions such as paraneoplastic
neurological disorders or CTD may be present [10,40]. Most of
the antibodies associated with these conditions can be detected by
IHC on monkey tissue sections, but not in the CBA. Therefore, a
combination of CBA and IHC is highly recommendable as it
permits to make use of the advantages of both methods.
Based on the present cohort, the assay yielded a very high
sensitivity (95%) for NMO. Jarius et al. previously evaluated part
of this kit (AQP4-transfected HEK cells) and found a slightly lower
sensitivity (78%) for NMO in their cohort [41]. In a smaller study
from our laboratory, we had found a 100% sensitivity for NMO
[36]. Kim et al. and Waters et al. recently reported a sensitivity of
78% and 60%, respectively, using the same CBA [42,43].
Importantly, however, all five studies consistently found a
specificity of 100% (based on a total of 357 controls).
Differences in samples size could be responsible for the
differences in sensitivity rates found between the various studies,
and the lower size of our study compared to previous ones could
thus represent a potential methodological limitation of our work.
However, the differences obtained between larger studies (78% in
two independent studies by Jarius et al. [N=32] [41] and Kim et
al. [N=65] [42], versus 60% in the study by Waters et al. [N=35]
[43]) suggests that factors other than samples size (age? sex?
genetic background? case ascertainment?) may possibly play a role
as well. Larger multicentric studies with homogeneous inclusion
and selection criteria are needed to definitely assess the frequency
of anti-AQP4 antibodies in NMO.
4/61 patients (1=NMO, 3=MS) analyzed in this study were
younger than 18 years at the time of blood sampling. However,
previous studies [44,45] have found a frequency of NMO-IgG/
anti-AQP4 in pediatric cohorts similar to that in adult patients.
Therefore, we consider it unlikely that the inclusion of 4 pediatric
patients in the present study has relevantly influenced our results.
It could have been a potential limitation that the clinical and
radiological criteria were evaluated by the treating physicians and
obtained by us by means of a questionnaire. However, the high
sensitivity and 100% specificity found in this study, which was
Table 3. Diagnostic sensitivity, specificity and likelihood ratios (LR+,L R 2) for NMO calculated for each single substrate of the
BioChip, obtained by testing 91 serum samples on the ‘‘Neurology Mosaic 17’’.
SENSITIVITY FOR NMO SPECIFICITY FOR NMO LR+ LR2
AQP4 TRANSFECTED CELLS 95% 100% ‘ 0.05
PRIMATE CEREBELLUM (Typical AQP4 white matter
staining)
95% 96% 23.75 0.05
PRIMATE CEREBRUM (Typical AQP4 white matter
staining)
95% 94% 15.83 0.05
PRIMATE OPTIC NERVE (Typical AQP4 white matter
staining)
95% 96% 23.75 0.05
NMO: neuromyelitis optica, LR: likelihood ratio.
doi:10.1371/journal.pone.0038896.t003
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tainties in patient classification in the present study.
After submission of our study, a very interesting comparison of
seven NMO-IgG/AQP4-IgG assays, including the CBA evaluated
here, was published [43]. The authors found that the CBA and an
in-house flow cytometry assay based assay (University of Oxford)
‘‘were the most sensitive assays’’, but pointed out that the expertise
and resources required to perform the flow cytometry assays would
‘‘preclude its use in small-scale clinical diagnostic laboratories’’. In
this study, the CBA was also compared to a commercially
available ELISA (RSR, UK). The authors found that the ELISA
had a slightly lower sensitivity when compared to the Euroimmun
CBA (CBA-E), which could be improved by using a cut-off value
lower than the one recommended by the manufacturer; however,
they concluded that sera yielding values below the manufacturer’s
cut-off ‘‘would require confirmatory specificity testing by CBA-E’’.
High intra- and inter-laboratory assay reproducibility is an
important pre-requisite for clinical trials. Therefore, we tested 91
serum samples in our laboratory (by two different operators) and,
in addition, 9 samples in parallel in our laboratory and, in a
blinded fashion, at the Institute for Experimental Immunology,
affiliated to Euroimmun, in Luebeck, Germany. We found a 100%
concordance between results (K=1).
In conclusion, the assay evaluated in the present study is
potentially suitable for future multi-centre studies in NMO
because of its very high sensitivity, specificity, and reproducibility.
We therefore strongly recommend including this assay in
upcoming trials comparing the diagnostic performance of the
various methods currently available for the detection of anti-AQP4
antibodies.
Acknowledgments
The authors thank Etienne Cassin for guidance with the fluorescence
microscopy and photographic measurements, and Egidio Caricati for his
help in revising the manuscript.
We also thank Alenia Areonautica S.p.A. for supporting the fellowship of
FM.
Author Contributions
Conceived and designed the experiments: LG, FM, PV, AB. Performed the
experiments: LG FM. Analyzed the data: LG FM PV. Contributed
reagents/materials/analysis tools: JF AKP PS PN MC. Wrote the paper:
LG FM SJ AB.
References
1. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG (1999) The
clinical course of neuromyelitis optica (Devic’s syndrome). Neurology
53(5):1107–1114.
2. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG
(2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 23:
66(10),1485–1489.
3. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, et al.
(2004) A serum autoantibody marker of neuromyelitis optica: distinction from
multiple sclerosis. Lancet 364: 2106–2112.
4. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker
of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp
Med 202: 473–477.
5. Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, et al. (2006)
Neuromyelitis optica IgG predicts relapse after longitudinally extensive
transverse myelitis. Ann Neurol 59: 566–569.
6. Jarius S, Frederikson J, Waters P, Paul F, Akman-Demir G, et al. (2010).
Frequency and prognostic impact of antibodies to aquaporin-4 in patients with
optic neuritis. J Neurol Sci 298(1–2): 158–162.
7. Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, et al. (2010)
Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated
optic neuritis. J Neurol Neurosurg Psychiatry 81: 109–111.
8. Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, et al. (2008)
Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 65(1):
78–83.
9. Wandinger KP, Stangel M, Witte T, Venables P, Charles P, et al. (2010)
Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic
lupus erythematosus and primary Sjogren’s syndrome. Arthritis Rheum 62(4):
1198–1200.
10. Jarius S, Jacobi C, de Seze J, Zephir H, Paul F, et al. (2011) Frequency and
syndrome specificity of antibodies to aquaporin-4 in neurological patients with
rheumatic disorders. Mult Sclerosis 17(9):1067–73.
11. Jarius S, Wildemann B (2010) AQP4 antibodies in neuromyelitis optica:
diagnostic and pathogenetic relevance. Nat Rev Neurol 6 (7): 383–392.
12. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. (2005)
Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘‘McDonald
Criteria’’. Ann Neurol 58 (6): 840–846.
13. Hilliam RM (2005) Statistical discrimination in the presence of selection effects.
Stat Med 24 (8): 1219–1232.
14. Landis JR, Koch GG (1977) The measurement of observer agreement for
categorical data. Biometrics 33: 159–174.
15. Kundel HL, Polansky M (2003) Measurement of observer agreement. Radiology
228: 303–308.
16. Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, et al. (2008)
NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 70:
2197–2200.
17. Shimizu J, Hatanaka Y, Hasegawa M, Iwata A, Sugimoto I, et al. (2010) IFNb-
1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica
spectrum. Neurology 75(16):1423–7.
18. Palace J, Leite MI, Nairne A, Vincent A (2010) Interferon Beta Treatment in
Neuromyelitis Optica. Arch Neurol 67(8):1016–1017.
19. Kleiter I, Hellwig K, Berthele A, Ku ¨mpfel T, Linker RA, et al (2012) Failure of
Natalizumab to Prevent Relapses in Neuromyelitis Optica. Arch Neurol
69(2):239–245.
20. Barnett MH, Prineas JW, Buckland ME, Parratt JDE, Pollard JD (2012) Massive
astrocyte destruction in neuromyelitis optica despite natalizumab therapy.
Multiple Sclerosis Journal 18(1) 108–112.
21. Min JH, Kim BJ, Lee KH (2012) Development of extensive brain lesions
following fingolimod (FTY720) treatment in a patient with neuromyelitis optica
spectrum disorder. Multiple Sclerosis Journal 18(1) 113–115.
22. Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, et al.
(2011) Azathioprine: tolerability, efficacy, and predictors of benefit in
neuromyelitis optica. Neurology 77(7):659–66.
23. Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, et al. (2011) Impact of
rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler
17(10):1225–30.
24. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ (2011) Repeated treatment with
rituximab based on the assessment of peripheral circulating memory B cells in
patients with relapsing neuromyelitis optica over 2 years. Arch Neurol
68(11):1412–20.
25. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, et al. (2005) An open label
study of the effects of rituximab in neuromyelitis optica. Neurology 64:1270–2.
26. Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, et al. Treatment
of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch
Neurol 2008; 65:1443–8.
27. Jarius S, Franciotta D, Bergamaschi R, Wright H, Littleton E, et al. (2007)
NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 68 (13): 1076–
1077.
28. De Vidi I, Boursier G, Delouche N, Portales P, Cadars E, et al. (2011) Strategy
for anti-aquaporin-4 auto-antibody identification and quantification using a new
cell-based assay. Clin Immunol 138: 239–246.
29. Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, et al. (2007) Anti-
aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on
antibody titre. Brain 130: 1235–1243.
30. Waters P, Jarius S, Littleton E, Leite MI, Jacob S, et al. (2008) Aquaporin-4
antibodies in neuromyelitis optica and longitudinally extensive transverse
myelitis. Arch Neurol 65 (7): 913–919.
31. Paul F, Jarius S, Aktas O, Bluthner M, Bauer O, et al. (2007) Antibody to
aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 4(4): e133.
32. McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, Hinson SR, et al. (2009)
Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and
specificities of immunohistochemical and immunoprecipitation assays. Arch
Neurol 66(9): 1134–1138.
33. Hayakawa S, Mori M, Okuta A, Kamegawa A, Fujiyoshi Y, et al. (2008)
Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-
linked immunosorbent assay. J Neuroimmunol 30: 196(1–2), 181–187.
34. Fazio R, Malosio ML, Lampasona V, De Feo D, Privitera D, et al. (2009)
Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis
optica patients. Mult Scler 15 (10): 1153–1163.
Assay for Neuromyelitis Optica Serology
PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e3889635. Kalluri SR, Illes Z, Srivastava R, Cree B, Menge T, et al. (2010) Quantification
and functional characterization of antibodies to native aquaporin 4 in
neuromyelitis optica. Arch Neurol 67(10): 1201–1208.
36. Marnetto F, Hellias B, Granieri L, Frau J, Patanella AK, et al. (2009) Western
blot analysis for the detection of serum antibodies recognizing linear Aquaporin-
4 epitopes in patients with Neuromyelitis Optica. J Neuroimmunol 217 (1–2):
74–79.
37. Fazio R, Radaelli M, Furlan R (2010) Neuromyelitis Optica: Concepts in
evolution.J Neuroimmunol 231(1–2): 100–104.
38. Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, et al. (2008) Antibody to
aquaporin-4 in the long-term course of neuromyelitis optica. Brain 131(Pt 11):
3072–3078.
39. Marignier R, De Seze J, Vukusic S, Durand-Dubief F, Zephir H, et al. (2008).
NMO-IgG and Devic’s neuromyelitis optica: a French experience. Mult Scler 14
(4): 440–445.
40. Jarius S, Wandinger KP, Borowski K, Stoecker W, Wildemann B (2012)
Antibodies to CV2/CRMP5 in neuromyelitis optica-like disease: Case report
and review of the literature. Clin Neurol Neurosurg 114(4):331–5.
41. Jarius S, Probst C, Borowski K, Franciotta D, Wildemann B, et al. (2010)
Standardized method for the detection of antibodies to aquaporin-4 based on a
highly sensitive immunofluorescence assay employing recombinant target
antigen. J Neurol Sc 291: 52–56.
42. Kim W, Lee JE, Li XF, Kim SH, Han BG, et al. (2011) Quantitative
measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent
assay using purified recombinant human aquaporin-4. Mult Scler Sep 30, in
press.
43. Waters PJ, McKeon A, Leite MI, Rajasekharan S, Lennon VA, et al. (2012)
Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG
assays. Neurology 78(9):665–71
44. Banwell B, Tenembaum S, Lennon VA, Ursell E, Kennedy J, et al. (2008)
Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS
disorders. Neurology 70(5):344–52. Epub 2007 Dec 19.
45. Lotze TE, Northrop JL, Hutton GJ, Ross B, Schiffman JS, et al. (2008)
Spectrum of pediatric neuromyelitis optica. Pediatrics 122(5):e1039–47
Assay for Neuromyelitis Optica Serology
PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e38896